United Therapeutics stock has delivered a strong 5 year run, yet its current valuation checks still lean toward the shares looking inexpensive rather than stretched, even as recent insider selling and fresh clinical and regulatory news give investors more to weigh.

• United Therapeutics has returned 184.8% over the past 5 years, which puts extra focus on whether the current share price still reflects a reasonable entry point after such a long period of gains.
• Recent FDA approval for the LungFX device and positive phase 3 data for nebulized Tyvaso can support expectations for future cash flows, while the chief executive's recent US$5.2m stock sale may prompt some shareholders to question how much upside is already reflected in the price.
• On Simply Wall St's broader checks, United Therapeutics screens as undervalued in 5 of 6 areas, which suggests the overall valuation picture still tilts toward the stock looking cheap rather than expensive.

The issue now is whether that combination of strong long term returns and a high value score leaves enough margin for error for new investors at today's price.

Is United Therapeutics Still Cheap on Earnings?

The P/E multiple is a relevant metric for United Therapeutics because the company is generating positive earnings and trades on a well-established market track record. United Therapeutics currently trades on a P/E of about 17.4x, which is close to the broader biotech industry average of 17.1x and below the peer group average of 20.3x. That places the stock roughly in line with the sector overall, while still at a discount to similar companies in the peer set.

The fair P/E suggested by the model, which adjusts for factors such as margins, size and risk, is 25.4x. Compared with the current 17.4x, that indicates the market is assigning a lower multiple than this framework suggests. Despite the recent LungFX approval and positive Tyvaso phase 3 data increasing interest in United Therapeutics, the earnings multiple remains below both the modelled fair level and the peer average.

On the P/E yardstick, United Therapeutics stock currently appears undervalued.

The United Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for United Therapeutics pick up where the P/E discussion leaves off by explaining which combinations of future growth, margins and earnings would need to hold for United Therapeutics' stock to be worth meaningfully more or less than it is today. Instead of stopping at a single output from a ratio or model, they show the underlying path that number relies on and give you something concrete to monitor over time on the Community page.

Community views on United Therapeutics sit far apart, with some investors focused on long runway potential and others worried about concentration risk and future competition.

Bull case: 29% undervalued

"United Therapeutics' unmatched leadership and real-world progress in groundbreaking technologies like xenotransplantation and organ manufacturing expose the company to entirely new, uncrowded multibillion-dollar markets..."

Bear case: roughly fairly valued

"While United Therapeutics has experienced sustained revenue growth fueled by Tyvaso DPI and a concentrated portfolio, this heavy reliance on a small number of key drugs exposes the company to severe patent expiration and generic/biosimilar risk over the long term..."

Do you think there's more to the story for United Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

United Therapeutics still screens as undervalued on earnings, with its current P/E sitting below both the peer group and the fair multiple suggested by broader checks. That discount sits alongside active product news and insider selling, which point in different directions for sentiment. For you, the key question is whether United Therapeutics can sustain the earnings profile that justifies a re rating or whether concentration and competitive risks mean the current multiple is closer to where it should be. The answer to that tension, rather than past returns, is what will matter most from here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.